Mark Goldberger, MD, MPH, FIDSA, has been appointed to the newly created position of medical director for emerging and pandemic threat preparedness in the Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER). Dr. Goldberger began working for the agency in 1989 as a medical reviewer and is currently the director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research (CDER).

George H. Talbot, MD, FIDSA, has been named chief medical officer and executive vice president of Cerexa Inc., a biopharmaceutical company focused on anti–infectives. Dr. Talbot was a founding member of IDSA’s Antimicrobial Availability Task Force, an author of the “Bad Bugs, No Drugs” White Paper, and the lead author of the recent Clinical Infectious Diseases article entitled, “Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.”

Ann M. Arvin, MD, FIDSA, has been appointed vice provost and dean of research at Lucile Packard Children’s Hospital in Palo Alto, Calif. Dr. Arvin is currently chief of the infectious disease division of the pediatrics department and has served as associate dean of research since 2001.

John D. Malone, MD, MPH, FIDSA, has been selected as program manager of the Center for Biological Monitoring and Modeling at the Pacific  Northwest National Laboratory in Richland, Wash. He recently retired as a captain in the Medical Corps of the United States Navy after 30 years of service, with final duty assignments as commanding officer of the USNS Mercy hospital ship and director for medical services of the Naval Medical Center, San Diego.